Agenda
**THIS AGENDA IS NO LONGER BEING UPDATED, PLEASE REFER TO THE TERRAPINN EVENTS APP**
Boston, 4 - 5 November 2026
Schedule
Create your personal agenda –check the favourite icon
Nov 48:55
Conference pass
Welcome Remarks
Keynotes
Chris Shanks, Conference Director, Advanced Therapies, Terrapinn
Nov 49:00
Conference pass
Chair's Opening Remarks
Keynotes
Gwendolyn Binder, President of Science and Technology, Cabaletta Bio
Nov 49:05
Conference pass
From Pipeline to Patients: Reflections on the gene therapy development journey
Keynotes
Nov 49:45
Conference pass
Keynote Panel Discussion: Navigating the Cell and Gene Therapy Landscape: Opportunities & Challenges for Driving Market Success
Keynotes
Tom Leitch, CTO, KSQ Therapeutics, Inc.
Anne Brooks, SVP, Global Access, Operations and Proleukin, Iovance Biotherapeutics
Brian Campbell, VP & GM, US, Orchard Therapeutics
Johanna Rossell, Senior Vice President, General Manager, Regenerative Medicine, Sumitomo Pharma America Inc
Nov 410:25
Conference pass
AI-Driven Small Molecules to Enhance Cell Therapy Potency and Persistence
Start-up Pitch (Track 5, Seminar Theatre)
T cell therapies are only as good as the cells that reach the patient, yet ex vivo manufacturing itself drives exhaustion and erodes the stem-like memory phenotypes that underpin durable response. We have built an AI-driven discovery platform that predicts novel intracellular targets and designs small molecules to address this at its source. Added during ex vivo expansion and washed out before infusion, these compounds act as manufacturing reagents rather than systemic drugs, allowing integration under a sponsor's existing IND without a standalone regulatory filing. In primary human T cells, our lead compound drives a roughly 16-fold increase in polyfunctionality, a twofold enrichment of stem-like memory cells, elevated TCF-1, and reduced exhaustion. Because the approach is target-driven and platform-based, it is modality-agnostic across CAR-T and next-generation cell therapies.
Nov 410:40
Conference pass
One Instrument, Every Vector: Empty/Full Ratio, Concentration and Aggregation in 10 Minutes on 10 µL, without Labelling or Calibration
Start-up Pitch (Track 5, Seminar Theatre)
Nov 411:05
Conference pass
Chair's Remarks: Chris Mason, Professor of Cell & Gene Therapy, University College London
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Nov 411:05
Conference pass
Chair's Remarks: Holger Russ, Scientific Co-Founder, Tolerance Bio
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Holger Russ, Scientific Co-Founder, Tolerance Bio
Nov 411:05
Conference pass
Chair's Remarks: Poh Yeh-Chuin, VP, Head of Tech Ops, Tolerance Bio
Supply Chain & Logistics (Track 6, Room 207)
Poh Yeh-Chuin, VP, Head of Tech Ops, Tolerance Bio
Nov 411:05
Conference pass
Chair's Remarks: Richard Koya, Professor, University of Chicago School of Medicine
Gene Modified Cell Therapy (Track 7, Room 208)
Nov 411:05
Conference pass
Chair's Remarks: Roy Baynes, Executive Vice President and Chief Medical Officer, Eikon Therapeutics
Innovation Showcase (Track 5, Seminar Theatre)
Roy Baynes, Executive Vice President and Chief Medical Officer, Eikon Therapeutics
Nov 411:05
Conference pass
Chair's Remarks: Roy Levitt, Clinical Professor, Director, UHealth Institute for Advanced Pain Management Center, University of Miami
Viral Vector Manufacturing (Track 3)
Nov 411:05
Conference pass
Chair's Remarks: Shahrooz Rabizadeh, CEO & Co-Founder, Sagittarius Bio, Inc
Gene Therapy (Track 4)
Shahrooz Rabizadeh, CEO & Co-Founder, Sagittarius Bio, Inc
Nov 411:05
Conference pass
Chair's Remarks: Sharon Anderson, VP of Scientific Affairs, Alliance for Regenerative Medicine
Evidence, Pricing & Access (Track 8, Room 209)
Sharon Anderson, VP of Scientific Affairs, Alliance for Regenerative Medicine
Nov 411:10
Conference pass
Building a Resilient Advanced Therapy Supply Chain for Drug Development: Practical Insights
Supply Chain & Logistics (Track 6, Room 207)
Tara Sadeghi, Chief Operating Officer, Cellenkos Inc.
Nov 411:10
Conference pass
Designing for Scale: Manufacturing Robust Allogeneic CAR-T Cell Therapies in Hematologic Malignancies
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Nov 411:10
Conference pass
Developing an effective value-based framework for HTA assessment markets
Evidence, Pricing & Access (Track 8, Room 209)
Anne Brooks, SVP, Global Access, Operations and Proleukin, Iovance Biotherapeutics
Nov 411:10
Conference pass
Gene therapy for cancer and inflammatory diseases
Gene Therapy (Track 4)
Shahrooz Rabizadeh, CEO & Co-Founder, Sagittarius Bio, Inc
Nov 411:10
Conference pass
Next-gen gene therapy manufacturing: Unlocking the promise of HSV
Viral Vector Manufacturing (Track 3)
Nov 411:10
Conference pass
Overcoming the NRF2 addiction in solid tumors using CRISPR-directed gene editing
Gene Modified Cell Therapy (Track 7, Room 208)
Eric Kmiec, Founder & CEO, Gene Editing Institute
Nov 411:10
Conference pass
The promises and challenges of IPS-derived cell therapies
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Nov 411:10
Conference pass
Value of regenerative medicine for rare disease
Innovation Showcase (Track 5, Seminar Theatre)
Johanna Rossell, Senior Vice President, General Manager, Regenerative Medicine, Sumitomo Pharma America Inc
Nov 411:30
Conference pass
Building, planning and executing an effective market access strategy for gene therapies
Evidence, Pricing & Access (Track 8, Room 209)
Nov 411:30
Conference pass
Disease agnostic gene therapy for neurodegenerative conditions
Gene Therapy (Track 4)
Nov 411:30
Conference pass
ELEVECTA™ stable producer cell line 2.0: A high-performance platform for AAV manufacturing cell lines
Viral Vector Manufacturing (Track 3)
ELEVECTA™ stable producer cell line 2.0: A high-performance platform for AAV manufacturing cell lines
The clinical and commercial success of adeno-associated virus (AAV)-based gene therapies continues to drive demand for manufacturing platforms capable of delivering high productivity, consistent product quality, and scalable production. However, many existing manufacturing approaches remain constrained by process complexity, high cost of goods, batch-to-batch variability, and challenges associated with scale-up and long-term process robustness. As the field matures, there is growing interest in technologies that can simplify manufacturing while meeting the increasing quality and supply demands of advanced therapy developers.
Stable producer cell lines have emerged as a promising strategy to address these challenges by reducing reliance on transient transfection workflows and enabling more standardized manufacturing processes. Developing robust producer cell lines that combine high productivity, favorable capsid quality attributes, and manufacturability within commercially relevant timelines remains a significant challenge.
To address this need, we present the ELEVECTA™ stable producer cell line 2.0, a HEK293-based platform designed to rapidly generate high-performing AAV manufacturing cell lines with strong productivity and favorable quality characteristics.
A high-throughput cell line engineering and screening workflow was established to systematically evaluate the impact of rep and helper funtions, regulatory, and host-cell engineering strategies on AAV production performance. Hundreds of genetic configurations were assessed using advanced analytical screening tools, enabling the rapid identification of cell line architectures associated with improved productivity and product quality. Selected ELEVECTA™ stable producer cell line 2.0 were subsequently evaluated across multiple AAV serotypes for key manufacturing attributes, including viral genome titre, capsid quality, encapsidated host-cell DNA, stability, and scalability.
Across independent cell line development campaigns, cell lines generated using this approach consistently achieved viral genome titres exceeding 5 × 10¹¹ vg/mL at the polyclonal pool stage, with further improvements observed following clonal selection. Favorable product quality characteristics were also demonstrated, with full capsid levels ranging from 20% to 50%, depending on serotype, accompanied by low levels of partial particles.
In addition, targeted host-cell engineering significantly reduced encapsidated host-cell DNA, supporting cleaner viral preparations and potentially reducing downstream purification burden. The integrated workflow enabled progression from construct design to fully banked producer clones in less than 24 weeks while maintaining robust cell growth and long-term production stability.
These findings demonstrate how the combination of high-throughput genetic screening, rational cell engineering, and accelerated clone selection can enable the rapid development of stable producer cell lines capable of supporting next-generation AAV manufacturing. By improving process consistency, accelerating development timelines, and enhancing manufacturing scalability, this approach has the potential to support more efficient production of AAV-based therapies from early development through commercial supply.
Nov 411:30
Conference pass
IPS-derived thymic cells for allogenic cell replacement therapy
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Holger Russ, Scientific Co-Founder, Tolerance Bio
Nov 411:30
Conference pass
Reimagining Gene-Modified T Cell Manufacturing: New Data on Integrating Isolation, Activation, Transduction, and Expansion in a Single Quantum Flex™ Workflow
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Summary:
Discover new data demonstrating a streamlined approach to gene-modified T cell manufacturing that integrates multiple critical unit operations into a single, closed workflow. This webinar will present the first demonstration of incorporating T cell isolation upstream of Quantum Flex™ processing, extending automation and process integration from cell selection through expansion.
Starting with Leukopak material collected on the Spectra Optia®, CD3+ T cells were isolated using a buoyancy-based microbubble separation method. Fewer than 10 million isolated and activated T cells were then directly introduced into the Quantum Flex system, where they underwent lentiviral transduction and expansion to a therapeutically relevant dose.
Key Takeaways:
- First demonstration of an integrated workflowcombining T cell isolation with Quantum Flex™ processing.
- End-to-end automationspanning cell isolation, activation, transduction, and expansion.
- Closed-system manufacturing approachdesigned to reduce open handling steps and operator intervention.
- Reduced hands-on processing timeand a shorter path from starting material to target cell dose.
- Robust expansion from a small starting cell numberwhile maintaining critical quality attributes.
- Comparison with traditional static culture methods, highlighting potential process efficiencies.
- Enhanced process consistency and scalabilitythrough integration of buoyant microbubble-based cell isolation with the Quantum Flex platform.
- Potential to simplify manufacturing operationsand support next-generation gene-modified T cell therapy production.
Join us to explore how an integrated, closed-system workflow could help advance cell therapy manufacturing through greater efficiency, flexibility, and process consistency.
Nov 411:30
Conference pass
Standardisation in apheresis collection for cellular starting materials
Supply Chain & Logistics (Track 6, Room 207)
Tracey Hlucky, Associate Director, Regional Quality Operations, Kite Pharma
Nov 411:30
Conference pass
Transforming treatment of autoimmune disease with effector T-cell therapy
Gene Modified Cell Therapy (Track 7, Room 208)
Gwendolyn Binder, President of Science and Technology, Cabaletta Bio
Nov 411:30
Conference pass
Using new approach methodologies for the development of novel immunotherapies
Innovation Showcase (Track 5, Seminar Theatre)
Nov 411:50
Conference pass
Developing a chimeric antigen receptor tumor cell therapy (car-tumor)
Gene Therapy (Track 4)
George Zhou, Founder & CEO, Joint Biosciences
Nov 411:50
Conference pass
Development of an AEX process for an engineered capsid ATC-0187
Viral Vector Manufacturing (Track 3)
Matthew Bennett, Head of Downstream Process Development, Affinia Therapeutics
Nov 411:50
Conference pass
End-to-end approaches for comparability in cell therapy manufacturing
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Alla Amcheslavsky, Team Lead, CMC Analytical Development, Astellas
Nov 411:50
Conference pass
Engineering progenitor cells for TCR based immunotherapies for solid tumours
Gene Modified Cell Therapy (Track 7, Room 208)
Nov 411:50
Conference pass
Modified self-amplifying RNA vaccines & therapeutics
Innovation Showcase (Track 5, Seminar Theatre)
Joshua McGee, CSO & Co-founder, Keylicon Biosciences
Nov 412:10
Conference pass
Fresh Matters: Reducing Pre-Analytical Risk in Human Biospecimen Access for Advanced Therapies
Start-up Pitch (Track 5, Seminar Theatre)
Patty Tawadros, Ceo, Donor X
Nov 413:10
Conference pass
Chair's Remarks: Chirag Khatiwala, Head of CMC and Technical Operations, Rarity PBC
Viral Vector Manufacturing (Track 3)
Nov 413:10
Conference pass
Chair's Remarks: Christopher Ballas, Global Commercial Lead, Custom Cell Products, Cook MyoSite Inc
Supply Chain & Logistics (Track 6, Room 207)
Christopher Ballas, Global Commercial Lead, Custom Cell Products, Cook MyoSite Inc
Nov 413:10
Conference pass
Chair's Remarks: Erin Harris, Chief Editor,Cell & Gene
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Erin Harris, Chief Editor, Cell & Gene
Nov 413:10
Conference pass
Chair's Remarks: Kate Excoffon, Founder and CEO, Gene Tx Optimized, LLC
Gene Therapy (Track 4)
Kate Excoffon, Founder and CEO, Gene Tx Optimized, LLC
Nov 413:10
Conference pass
Chair's Remarks: Miguel Forte, CEO, Kiji Therapeutics and President, International Society of Cell and Gene Therapy
Gene Modified Cell Therapy (Track 7, Room 208)
Nov 413:10
Conference pass
Chair's Remarks: Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, FDA
Evidence, Pricing & Access (Track 8, Room 209)
Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, Food and Drug Administration (FDA)
Nov 413:10
Conference pass
Chair's Remarks: Preet Chaudhary, CEO, Angeles Therapeutics and Professor of Medicine and Chief of BMT and Cellular Therapy, University of Southern California
Innovation Showcase (Track 5, Seminar Theatre)
Nov 413:10
Conference pass
Chair's Remarks: Ray Dogum, Chief Editor, Life Science Connect
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Ray Dogum, Chief Editor, Drug Discovery Online
Nov 413:15
Conference pass
Accessing high value cell therapies: Accelerating CAR-T adoption
Evidence, Pricing & Access (Track 8, Room 209)
Sharon Anderson, VP of Scientific Affairs, Alliance for Regenerative Medicine
Nov 413:15
Conference pass
Cell therapy optimisation: Sourcing and engineering
Gene Modified Cell Therapy (Track 7, Room 208)
Nov 413:15
Conference pass
Developing personal vaccines that target infectious diseases and cancer using an autologous cell platform
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Nov 413:15
Conference pass
Enhanced and integrated control strategy for cell therapies
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Nov 413:15
Conference pass
Exploring the back-end complexities of your supply chain
Supply Chain & Logistics (Track 6, Room 207)
Christopher Ballas, Global Commercial Lead, Custom Cell Products, Cook MyoSite Inc
Nov 413:15
Conference pass
Exploring the opportunities of longevity medicine
Innovation Showcase (Track 5, Seminar Theatre)
Fiona Miller, Managing Partner, quadraScope Ventures
Nov 413:15
Conference pass
Plant-based manufacturing for AAV gene therapy: Update on GMP pilot
Viral Vector Manufacturing (Track 3)
George Magrath, CEO, Opus Genetics
Nov 413:15
Conference pass
Update from Genethon: Applications of technological platforms
Gene Therapy (Track 4)
Angela Columbano, Head Business Development and Partnership, Genethon
Nov 413:35
Conference pass
A simplified, serum‑free T cell workflow powered by TheraPEAK® solutions
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Abstract: Serum is a major source of variability in T cell manufacturing, driving lot-to-lot inconsistency, sourcing constraints, and contamination risk. This data-led session shows you how a chemically defined, serum-free workflow removes that dependency, so you can build more reproducible processes from early development through clinical scale.
This presentation examines experimental data on the impact of serum removal at each stage of manufacturing: improved lentiviral vector transduction efficiency, robust T cell expansion in serum-free culture, and clinical-scale performance across multiple platforms. You will see cross-platform results spanning T-flasks, G-Rex, Xuri, and Cocoon systems, plus practical evidence on how oxygen transfer and media exchange strategies shape expansion outcomes. Key points takeaways include:
- A data-backed framework for evaluating and implementing serum-free T cell culture in your own workflows
- Experimental data showing improved lentiviral vector transduction efficiency and consistent expansion after serum removal
- Cross-platform scale-up performance across T-flasks, G-Rex, Xuri, and Cocoon systems, from research through clinical manufacturing
- Critical success factors that determine a successful transition, including cell handling, media management, and dissolved oxygen control
Nov 413:35
Conference pass
Accelerating healthcare innovation through strategic partnerships
Innovation Showcase (Track 5, Seminar Theatre)
Nov 413:35
Conference pass
Bioanalytical and analytical strategies for CAR-T Cell Therapies
Gene Modified Cell Therapy (Track 7, Room 208)
Nov 413:35
Conference pass
Evolution of Patient Access for Collection of Starting Material
Supply Chain & Logistics (Track 6, Room 207)
Natascha Nolet, Sr. Manager, Abeona Therapeutics
Nov 413:35
Conference pass
From Delivery Vehicle to Cells: Enabling In Vivo CAR Development with Integrated End-to-End Solutions
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
In vivo CAR therapy is emerging as a transformative approach that enables direct immune cell engineering within patients using delivery platforms such as lentiviral vectors (LVVs) and lipid nanoparticles (LNPs). While recent clinical advances have validated the potential of this modality, significant challenges remain in achieving efficient cell-specific delivery, characterizing delivery vehicles, and monitoring CAR expression. To address these needs, ACROBiosystems has developed an integrated platform to support the development and evaluation of targeted in vivo CAR therapeutics. The platform combines immune cell-targeting binder discovery, quantitative characterization of antibody-decorated LNPs, assessment of cellular uptake and intracellular trafficking, and sensitive CAR detection using fluorescently labeled recombinant proteins, anti-idiotypic antibodies, and universal CAR detection reagents. Our studies demonstrate that functional ligand accessibility, rather than total ligand density alone, is a key determinant of targeting performance, highlighting the importance of robust analytical characterization during nanoparticle development. These tools further enable sensitive detection of CAR-expressing cells in both engineered cell populations and whole blood samples. Together, this integrated workflow provides critical solutions for evaluating targeting efficiency, delivery performance, and CAR expression, helping accelerate the development and clinical translation of next-generation in vivo CAR therapies.
Nov 413:35
Conference pass
Generating Meaningful Evidence using the MED (Mechanistic Endpoint Definition) Framework
Evidence, Pricing & Access (Track 8, Room 209)
Luis Rojas-Graterol, Sr. Vice President & Head of Biometrics, INCSD LLC
Nov 413:35
Conference pass
How can educational programs support the field of cell therapy
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Nov 413:35
Conference pass
Next generation AAV manufacturing platform: Productivity, product quality and scalability up to 2,000 litre bioreactor
Viral Vector Manufacturing (Track 3)
Paetrice Jones, Associate Director, Genomic Medicine Cell Culture Process Development, Sanofi
Nov 413:35
Conference pass
PaVe-GT platform: Developing AAV gene therapies for rare diseases
Gene Therapy (Track 4)
Richa Madan Lomash, Therapeutic Development Project Manager, NIH
Nov 413:55
Conference pass
AI virtual cell for cell engineering and manufacturing optimization
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Rita Barcia, Cell, Gene & Immunotherapy Consultant, Barcia Novel Therapies
Nov 413:55
Conference pass
AI-driven decision-making platform for genomic medicine production
Innovation Showcase (Track 5, Seminar Theatre)
Irene Rombel, CEO and Co-Founder, BioCurie
Nov 413:55
Conference pass
Gene editing off-target nomination and validation for biological products
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Qianhua Dong, Senior Scientist, Legend Biotech
Nov 413:55
Conference pass
Opportunities and challenges for in vivo cell therapy
Gene Modified Cell Therapy (Track 7, Room 208)
Yu (Clay) Cao, Managing Director, CADA Biosciences
Nov 413:55
Conference pass
Packaging, distribution and clinical considerations for cell therapy drug product
Supply Chain & Logistics (Track 6, Room 207)
Shankar Swaminathan, Team Lead Drug Product Readiness CMC, Astellas
Nov 413:55
Conference pass
Starting early to develop evidence to support access & pricing for rare diseases
Evidence, Pricing & Access (Track 8, Room 209)
Ramesh Arjunji, Executive Vice President, Value & Access, Nanoscope Therapeutics
Nov 413:55
Conference pass
The optimism of optogenetics for vision restoration
Gene Therapy (Track 4)
Zhenghong Gao, COO, Cofounder, Uni-Pioneers, Bio-Med. Inc
Nov 413:55
Conference pass
Workforce development to support vector manufacturing processes
Viral Vector Manufacturing (Track 3)
David Zuzga, Associate Dean of Biomedical Studies, The Wistar Institute
Nov 414:15
Conference pass
Clinical-Grade Armored BCMA CAR T Cells Overcome TGF-β–Mediated Immunosuppression in Multiple Myeloma
Gene Modified Cell Therapy (Track 7, Room 208)
Deepak Parashar, Assistant Professor, Medical College of Wisconsin
Nov 414:15
Conference pass
Nov 414:15
Conference pass
Optimising commercial field teams to support complex health systems
Evidence, Pricing & Access (Track 8, Room 209)
Andrea Penn, Sr. Director, Customer Training & Field Excellence , Autolus
Nov 414:15
Conference pass
Scaling the Next Wave of Gene Therapies: Innovations in Lentiviral Vector Manufacturing
Viral Vector Manufacturing (Track 3)
Francesca Vitelly, Vice President & Global Head of Process, Analytical Development and Innovation, Minaris
Nov 414:15
Conference pass
Starting with the Patient: BMS’s Journey Toward Timely Cell Therapy Process Control Through Earlier Insights
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Nandini Anant, Associate Director, Process Engineering, Global Cell Therapy Technical Operations, Bristol Myers Squibb
Nov 414:15
Conference pass
Targeted delivery of advanced therapies and other medicinal payloads
Innovation Showcase (Track 5, Seminar Theatre)
Ricardo Baptista, Chief Technology Officer, SmartCella
Nov 414:35
Conference pass
Developing an autologous muscle cell therapy for women’s health
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Parul Nisha, Senior Director, Clinical and Medical Affairs, Cook MyoSite Inc
Nov 414:35
Conference pass
Latest developments in late phase process development
Viral Vector Manufacturing (Track 3)
Nov 414:35
Conference pass
Leveraging RWE to support clinical development for orphan diseases
Evidence, Pricing & Access (Track 8, Room 209)
Alex Sherman, Director, Center for Innovation and BioInformatics, Mass General Brigham
Nov 414:35
Conference pass
Logistical complexity reduction for early-stage clinical trials
Supply Chain & Logistics (Track 6, Room 207)
Tatyana Matveeva, Director of cGMP Operations, Mass General Hospital
Nov 414:35
Conference pass
Mindset and skillset revolution in hiring to meet the emerging workforce needs
Innovation Showcase (Track 5, Seminar Theatre)
Vishal Shah, Dean, Division of the Math, Science and Health Careers, Community College of Philadelphia
Nov 414:35
Conference pass
Pioneering next-generation targeted gene therapies for neurological disorders
Gene Therapy (Track 4)
Roelof Rongen, CEO, Adolore Biotherapeutics
Nov 414:35
Conference pass
Precision bio materials for T-cell modulation
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Xiao Huang, Assistant Professor, Precision Immune Engineering Laboratory, Drexel University
Nov 414:35
Conference pass
The first CRISPR edited clinical TIL therapy: From pre-clinical to translational
Gene Modified Cell Therapy (Track 7, Room 208)
Karrie Wong, VP of Cell Therapy, KSQ Therapeutics, Inc.
Nov 414:55
Conference pass
Act for Hope: Moving advocacy to action to increase patient access
Evidence, Pricing & Access (Track 8, Room 209)
Susan Nichols, Chief Executive Officer, Propel Biosciences
Nov 414:55
Conference pass
Cell Therapy Manufacturing Re-engineered
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Nov 414:55
Conference pass
Computational modeling and machine learning for scalable, cost-effective rAAV production
Viral Vector Manufacturing (Track 3)
Francesco Destro, Principal Engineer, BioCurie
Nov 414:55
Conference pass
Controlling Ice Recrystallization for Improved Cell Cryopreservation
Innovation Showcase (Track 5, Seminar Theatre)
Nov 414:55
Conference pass
Developing a Strategic Framework to Win for Patients in a Maturing CGT Landscape
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Philip Wills, Chief Commercial Officer, Catalent, Inc.
Nov 414:55
Conference pass
Insight on the Parkinson’s Disease Program: How targeting a genetic population enables entry into a larger market of sporadic PD?
Gene Therapy (Track 4)
Jennifer Johnston, Cofounder and CEO, NysnoBio
Nov 414:55
Conference pass
The Significance of the Traceability of Chain of Identity through Cold Chain Logistics
Supply Chain & Logistics (Track 6, Room 207)
Morgan Wolfe, Associate Director, Patient Operations, Abeona Therapeutics
Nov 414:55
Conference pass
The use of CAR-T reg to treat chronic inflammatory disease
Gene Modified Cell Therapy (Track 7, Room 208)
Sophie Blondel, Co-founder & CEO, Foxbio
Nov 415:15
Conference pass
AAV-based gene therapy of human prion diseases (CJD)
Gene Therapy (Track 4)
Qingzhong Kong, Associate Professor, Lab PI, Case Western Reserve University
Nov 415:15
Conference pass
Accurate modelling of cell therapy GMP yields to ensure clinical supply
Supply Chain & Logistics (Track 6, Room 207)
Spencer Hoover, Principal, SH Consulting LLC
Nov 415:15
Conference pass
AI-driven discovery of novel CAR-T cells
Gene Modified Cell Therapy (Track 7, Room 208)
Daniel Baker, PhD, University of Pennsylvania
Nov 415:15
Conference pass
Developing new methods to decipher malignant processes for GBM
Innovation Showcase (Track 5, Seminar Theatre)
Nov 415:15
Conference pass
Exploring the structural and systemic barriers of access to CGTs
Evidence, Pricing & Access (Track 8, Room 209)
Nov 415:15
Conference pass
Manufacturing consistency in autoimmune diseases
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Yan Li, Senior Director, Process Development, Cabaletta Bio
Nov 415:15
Conference pass
Product over process: Achieving success in cell therapies
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Arnaud Deladeriere, President and Principal Consultant, Cell&Gene Consulting
Nov 415:35
Conference pass
First in class T-cell directed CD6/CTLA4 CAR-Tregs for Autoimmune Disease
Gene Modified Cell Therapy (Track 7, Room 208)
Daniel Shelly, Chief Business Development Officer, Immuthera
Nov 415:35
Conference pass
Next generation cell therapy using novel chimeric antigen receptor T cell and NK cell platforms
Innovation Showcase (Track 5, Seminar Theatre)
Nov 415:35
Conference pass
Novel riboswitch for gene therapy
Gene Therapy (Track 4)
Xuecui Guo, SVP, Gene Regulation, MeiraGTx
Nov 415:35
Conference pass
QA considerations for supply chain and the applications of AI tools in QA for a cell therapy processing lab
Supply Chain & Logistics (Track 6, Room 207)
Ashita Chauhan, Quality Coordinator, Connecticut Children’s Hospital
Nov 415:35
Conference pass
Restoring Immune Balance: A Thymus-First Approach to Human Healthspan
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Poh Yeh-Chuin, VP, Head of Tech Ops, Tolerance Bio
Nov 416:25
Conference pass
Chair's Remarks: Craig T. Martin, Professor of Chemistry, University of Massachusetts
Innovation Showcase (Track 5, Seminar Theatre)
Nov 416:25
Conference pass
Chair's Remarks: Hernando Lopez-Bertoni, Associate Professor, Johns Hopkins School of Medicine
Gene Modified Cell Therapy (Track 7, Room 208)
Hernando Lopez-Bertoni, Associate Professor, Johns Hopkins Medicine
Nov 416:25
Conference pass
Chair's Remarks: Katie Hodges, President and Owner, KAH Management, LLC
Supply Chain & Logistics (Track 6, Room 207)
Katie Hodges, President and Owner, KAH Management, LLC
Nov 416:25
Conference pass
Chair's Remarks: Michael White, Founder ViroSpark
Viral Vector Manufacturing (Track 3)
Michael White, Founder, ViroSpark
Nov 416:25
Conference pass
Chair's Remarks: Ray Dogum, Chief Editor, Drug Discovery Online
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Ray Dogum, Chief Editor, Drug Discovery Online
Nov 416:25
Conference pass
Chair's Remarks: Scott Donohue, Senior Director, Market Access, Deerfield Management
Evidence, Pricing & Access (Track 8, Room 209)
Nov 416:25
Conference pass
Chair's Remarks: Scott Jeffers, Chief Technology Officer, GenSight Biologics
Gene Therapy (Track 4)
Scott Jeffers, Chief Technology Officer, GenSight Biologics
Nov 416:25
Conference pass
Chair's Remarks: Yan Li, Senior Director, Process Development, Cabaletta Bio
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Yan Li, Senior Director, Process Development, Cabaletta Bio
Nov 416:30
Conference pass
Applications of nanomedicine for stroke
Innovation Showcase (Track 5, Seminar Theatre)
Oscar Marcos Contreras, Assistant Professor, Temple University
Nov 416:30
Conference pass
Challenges and considerations for Medicaid coverage: Perspective from rural America
Evidence, Pricing & Access (Track 8, Room 209)
Terry Cothran, Chief Pharmacy Officer, Oklahoma Health Care Authority
Nov 416:30
Conference pass
Considerations and challenges for the apheresis collection process
Supply Chain & Logistics (Track 6, Room 207)
Yvette Tanhehco, Associate Professor of Pathology and Cell Biology, Medical Director of Cellular Therapy Laboratory, Columbia University
Nov 416:30
Conference pass
Leveraging automation to enable continuous manufacturing
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Nov 416:30
Conference pass
Mastering hcDNA in AAV Gene Therapies
Viral Vector Manufacturing (Track 3)
Haiqing Yu, Principal Scientist, Team Manager & Tech Lead, Sanofi
Nov 416:30
Conference pass
Mechanisms and consequences of DNA integration
Gene Therapy (Track 4)
Nov 416:30
Conference pass
Non-invasive tracking and imaging assessment of in vivo and ex vivo cell and gene therapies
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Mya Thu, Co-Founder and Chief Executive Officer, Visicell Medical Inc.
Nov 416:30
Conference pass
Non-viral immune cell therapy for oncology & autoimmune diseases
Gene Modified Cell Therapy (Track 7, Room 208)
howard Wu, CEO, Full Circles Therapeutics
Nov 416:50
Conference pass
Access pathways: Optimizing CGT access
Evidence, Pricing & Access (Track 8, Room 209)
Nov 416:50
Conference pass
AI for Genomic Medicine: Reprogramming Cell State for Neurological and Psychiatric Disease
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Nov 416:50
Conference pass
Breakthroughs in manufacturing of ultra-pure mRNA
Innovation Showcase (Track 5, Seminar Theatre)
Nov 416:50
Conference pass
Enhancing viral vector infectivity through modulating acting dynamics
Viral Vector Manufacturing (Track 3)
Yuntao Wu, Professor, George Mason University
Nov 416:50
Conference pass
Harnessing technological innovation to perform effective in vivo T-cell modification
Gene Modified Cell Therapy (Track 7, Room 208)
Cecile BAUCHE, CSO, Alaya.bio
Nov 416:50
Conference pass
How agentic AI is reshaping CMC?
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Nov 416:50
Conference pass
Panel Discussion: Harnessing Technological Innovation to Optimise Supply Chain and Logistics in Advanced Therapies
Supply Chain & Logistics (Track 6, Room 207)
Moderator: Katie Hodges, President and Owner, KAH Management, LLC
Christopher Ballas, Global Commercial Lead, Custom Cell Products, Cook MyoSite Inc
Spencer Hoover, Principal, SH Consulting LLC
Tracey Hlucky, Associate Director, Regional Quality Operations, Kite Pharma
Nov 416:50
Conference pass
Precise, RNA-meditated insertion of transgenes in mice, rats, and NHPs
Gene Therapy (Track 4)
Nov 417:10
Conference pass
Panel Discussion: Advancing Cell Therapy Manufacturing: Embracing AI, Automation and Digitalisation
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Moderator: Erin Harris, Chief Editor, Cell & Gene
David Zuzga, Associate Dean of Biomedical Studies, The Wistar Institute
Xiao Huang, Assistant Professor, Precision Immune Engineering Laboratory, Drexel University
Arnaud Deladeriere, President and Principal Consultant, Cell&Gene Consulting
Daniel Baker, PhD, University of Pennsylvania
Shankar Swaminathan, Team Lead Drug Product Readiness CMC, Astellas
David Smith, Vice President & Head of Development, Made Scientific
Nov 417:10
Conference pass
Panel Discussion: Building the Advanced Therapies Workforce of the Future: Improving Skills, Diversity and Training
Innovation Showcase (Track 5, Seminar Theatre)
Moderator: Vishal Shah, Dean, Division of the Math, Science and Health Careers, Community College of Philadelphia
Vladimir Bermudez, Associate Director, Columbia Institute for Cell Engineering and Therapy, Columbia Initiative in Cell Engineering and Therapy
Parul Nisha, Senior Director, Clinical and Medical Affairs, Cook MyoSite Inc
Ricardo Baptista, Chief Technology Officer, SmartCella
Susan Nichols, Chief Executive Officer, Propel Biosciences
Nov 417:10
Conference pass
Panel Discussion: Emerging Trends and Opportunities in Gene Therapy Development
Gene Therapy (Track 4)
Moderator: Kate Excoffon, Founder and CEO, Gene Tx Optimized, LLC
Zhenghong Gao, COO, Cofounder, Uni-Pioneers, Bio-Med. Inc
Scott Jeffers, Chief Technology Officer, GenSight Biologics
George Magrath, CEO, Opus Genetics
Roelof Rongen, CEO, Adolore Biotherapeutics
Shahrooz Rabizadeh, CEO & Co-Founder, Sagittarius Bio, Inc
Jennifer Johnston, Cofounder and CEO, NysnoBio
Nov 417:10
Conference pass
Panel Discussion: Exploring Next Generation Viral Vectors and Emerging Vector Delivery Systems
Viral Vector Manufacturing (Track 3)
Angela Columbano, Head Business Development and Partnership, Genethon
Matt Edwards, Vice President, Process Science, Affinia Therapeutics
Nov 417:10
Conference pass
Panel Discussion: Innovation In Gene Editing - Leveraging Platform Technology to Enhance Development Efficiency
Gene Modified Cell Therapy (Track 7, Room 208)
Eric Kmiec, Founder & CEO, Gene Editing Institute
Yu (Clay) Cao, Managing Director, CADA Biosciences
howard Wu, CEO, Full Circles Therapeutics
Cecile BAUCHE, CSO, Alaya.bio
Wenning Qin, Senior VP, Innovation & Process Development, eGenesis Inc
Nov 417:10
Conference pass
Panel Discussion: Overcoming Barriers and Expanding Access to Cell and Gene Therapies
Evidence, Pricing & Access (Track 8, Room 209)
Moderator: Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, Food and Drug Administration (FDA)
Holger Russ, Scientific Co-Founder, Tolerance Bio
Terry Cothran, Chief Pharmacy Officer, Oklahoma Health Care Authority
Ramesh Arjunji, Executive Vice President, Value & Access, Nanoscope Therapeutics
Nov 417:10
Conference pass
Panel Discussion: When’s the right time to start planning for commercial launch?
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Moderator: Kelli Tea, Head of Commercial, Cartesian Therapeutics
Roy Baynes, Executive Vice President and Chief Medical Officer, Eikon Therapeutics
Daniel KIlbank, CSO, Mygogenesis LLC
Craig Martin, Founder, CEO, Orphan Therapeutics Accelerator
Daniel Shelly, Chief Business Development Officer, Immuthera
Create your personal agenda –check the favourite icon
Nov 58:50
Conference pass
Chair’s Opening Remarks
Keynotes
Julianna LeMieux, Deputy Editor in Chief, Genetic Engineering & Biotechnology News
Nov 58:55
Conference pass
An Integrated Engine for Advanced Therapies: City of Hope Partner-Ready Engine for Clinical Translation
Keynotes
Vanessa Almendro Navarro, Chief Commercialization Officer, City of Hope
Nov 59:15
Conference pass
Lessons learned from filing a BLA based on a single arm trial design
Keynotes
Cokey Nguyen, President and CEO, Atara Biotherapeutics
Nov 59:35
Conference pass
Keynote Panel Discussion: Where’s the Money? Evolution And Future Outlook for Investment in Advanced Therapies
Keynotes
Moderator: Sven Kili, Partner, Saisei Ventures
Tay Salimullah, Venture Partner, 4BIO Capital
Renaud Vaillant, President, Alaya.bio
Nov 510:15
Conference pass
Leveraging the power of gene editing for extending the human lifespan
Keynotes
Nov 511:00
Conference pass
Roundtable 1: From Innovation to patient access: Exploring the role of platform technologies
Keynotes
Moderator: David Morrow, Scientific Lead for Advanced Therapies, EATRIS
Nov 511:00
Conference pass
Roundtable 2: In vivo gene editing of immune cells: CAR-T & Beyond
Keynotes
Moderator: David Peritt, Chief Scientific Officer, Lupagen
Nov 511:00
Conference pass
Roundtable 3: Autologous Vs Allogenic cell therapies
Keynotes
Nov 511:00
Conference pass
Roundtable 4: Tech transfer and scaling-up for the success of cell therapy programs
Keynotes
Nov 511:00
Conference pass
Roundtable 5: Convergence of RNA and cell therapy developments: What are the overlaps?
Keynotes
Moderator: James Carroll, CEO, RNA Nanobiotics
Nov 511:00
Conference pass
Roundtable 6: From ideation to successful execution: Surviving the valley of death
Keynotes
Moderator: Ram Mandalam, CEO, Stealth Biotech
Nov 511:00
Conference pass
Roundtable 7: Navigating the complex regulatory and compliance requirements for GMP sites
Keynotes
Moderator: Tatyana Matveeva, Director of cGMP Operations, Mass General Hospital
Moderator: Kunjan Kamdar, Director Quality Assurance & Regulatory Affairs at Laboratory for Cell & Gene Medicine, Stanford GMP Facility: Laboratory for Cell and Gene Medicine
Nov 511:00
Conference pass
Roundtable 8: Taking cell therapies across the BLA finishing line: Process development considerations
Keynotes
Moderator: Pooja Sabhachandani, Associate Director, Science and Technology, Novartis
Nov 513:00
Conference pass
Chair's Remarks: Chien-Tsun Kuan, President / CEO and Co-Founder, ARCE Therapeutics, Inc.
Gene Modified Cell Therapy (Track 7, Room 208)
Chien-Tsun Kuan, President / CEO and Co-Founder, ARCE Therapeutics Inc.
Nov 513:00
Conference pass
Chair's Remarks: David Morrow, Scientific Lead for Advanced Therapies, EATRIS
Innovation Showcase (Track 5, Seminar Theatre)
David Morrow, Scientific Lead for Advanced Therapies, EATRIS
Nov 513:00
Conference pass
Chair's Remarks: Kok-Seong Lim, Independent Expert
Viral Vector Manufacturing (Track 3)
Nov 513:00
Conference pass
Chair's Remarks: Michael McMahon, Professor, Johns Hopkins School of Medicine and Kennedy Krieger Institute
Gene Therapy (Track 4)
Michael McMahon, Professor, Johns Hopkins School of Medicine and Kennedy Krieger Institute, John Hopkins School Of Medicine
Nov 513:00
Conference pass
Chair's Remarks: Prachi Narayan, Independent Expert
Pre-Clinical & Clinical (Track 6, Room 207)
Prachi Narayan, End-to-End Clinical & Development Lead and Strategic Advisor– ATMPs, Independent Expert
Nov 513:00
Conference pass
Chair's Remarks: Ruud Hulspas, Director Process Development, Dana Farber Cancer Institute
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Ruud Hulspas, Director Process Development, Dana-Farber Cancer Institute
Nov 513:00
Conference pass
Chair's Remarks: Snehal Naik, VP of Science and Regulatory Affairs, BIO
Regulatory Affairs & Policy (Track 8, Room 209)
Snehal Naik, VP of Science and Regulatory Affairs, Biotechnology Innovation Organization (BIO)
Nov 513:00
Conference pass
Chair's Remarks: Yuntao Wu, Professor, George Mason University
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Yuntao Wu, Professor, George Mason University
Nov 513:05
Conference pass
Best practice for process development in cell therapy manufacturing
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Ruud Hulspas, Director Process Development, Dana-Farber Cancer Institute
Nov 513:05
Conference pass
Bridging the Gap Between Discovery and Clinical Translation for a Base-Edited CART/CD34 Tandem Product
Pre-Clinical & Clinical (Track 6, Room 207)
Friederike Herbst-Nowrouzi, Director of the Human Genome Editing Laboratory (HGEL), Perelman School of Medicine University of Pennsylvania
Nov 513:05
Conference pass
CAR-T cell therapy for solid tumours
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Prasad Adusumilli, Deputy Chief, Thoracic Surgery, Vice Chair, Department Of Surgery, Memorial Sloan-Kettering Cancer Center
Nov 513:05
Conference pass
CD74 CAR-T to treat lymphoma
Pre-Clinical & Clinical (Track 6, Room 207)
Nov 513:05
Conference pass
Effectively interacting with regulatory authorities
Regulatory Affairs & Policy (Track 8, Room 209)
Nov 513:05
Conference pass
Maximising yield of full particles by optimised payloads
Viral Vector Manufacturing (Track 3)
Nov 513:05
Conference pass
New delivery technologies that target new unmet disease indications
Gene Modified Cell Therapy (Track 7, Room 208)
Nov 513:05
Conference pass
Next-generation of stem cell derived pancreatic beta cells for cell therapies
Innovation Showcase (Track 5, Seminar Theatre)
Holger Russ, Scientific Co-Founder, Tolerance Bio
Nov 513:05
Conference pass
Theranostic gene delivery vehicles
Gene Therapy (Track 4)
Michael McMahon, Professor, Johns Hopkins School of Medicine and Kennedy Krieger Institute, John Hopkins School Of Medicine
Nov 513:25
Conference pass
Exploring the value of donor selection & characterisation for CIR™NK cells
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Nov 513:25
Conference pass
How do the new regulatory flexibilities incentivize rare disease therapies for commercial CGT development?
Regulatory Affairs & Policy (Track 8, Room 209)
Nov 513:25
Conference pass
Manufacturing Innovation and Operational Excellence to Boost a Cell Therapy Development Engine
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Nov 513:25
Conference pass
Manufacturing procedures for retro viral vectors in an academic setting
Viral Vector Manufacturing (Track 3)
Xiuyan Wang, Director of Cell Therapy Core Facility, Memorial Sloan-Kettering Cancer Center
Nov 513:25
Conference pass
Moving gene editing beyond the liver
Gene Modified Cell Therapy (Track 7, Room 208)
Nov 513:25
Conference pass
Shaping the current environment to support the commercialization of gene therapies
Gene Therapy (Track 4)
Christina Hartman, Head of Government Affairs and Washington, DC Office, Orchard Therapeutics
Nov 513:25
Conference pass
The Mygotic Process, The Next Advancement in Autologous Totipotent Stem Cells from Somatic Cells
Innovation Showcase (Track 5, Seminar Theatre)
Nov 513:25
Conference pass
Translating cell & gene therapies into the clinic from academia
Pre-Clinical & Clinical (Track 6, Room 207)
Nov 513:45
Conference pass
A Novel AEX Chromatography Method for Full Capsid Enhancement
Viral Vector Manufacturing (Track 3)
Wenjun Di, Senior Scientist, Ultragenyx Pharmaceutical Inc.
Nov 513:45
Conference pass
Alternative models for advancing and commercialising gene modified cell therapies
Gene Modified Cell Therapy (Track 7, Room 208)
Craig Martin, Founder, CEO, Orphan Therapeutics Accelerator
Nov 513:45
Conference pass
Development of macrophage-based cell therapies for the treatment of solid tumors
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Koby Kidder, Head of R&D, Co-Inventor, BobcatBio
Nov 513:45
Conference pass
Development of potency assays for manufacturing of advanced therapies
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Therese Choquette, Chief Technical Officer, Tigen Pharma
Nov 513:45
Conference pass
Leveraging epigenetic editing for transformative medicine
Gene Therapy (Track 4)
Nov 513:45
Conference pass
Next generation of gene therapy delivery
Innovation Showcase (Track 5, Seminar Theatre)
Nov 513:45
Conference pass
Overview and adapting to the current regulatory landscape in the US
Regulatory Affairs & Policy (Track 8, Room 209)
Jim Wang, VP, Global Regulatory Strategy, Genetic Medicines, Regeneron
Nov 513:45
Conference pass
Regulatory considerations for clinical trial design
Pre-Clinical & Clinical (Track 6, Room 207)
Nov 514:05
Conference pass
Driving Cell & Gene Therapies with DashCAR® toward Clinical Study for Cancer Treatment
Gene Modified Cell Therapy (Track 7, Room 208)
Chien-Tsun Kuan, President / CEO and Co-Founder, ARCE Therapeutics Inc.
Nov 514:05
Conference pass
How to Build the Manufacturing and Supply Strategy Into an Industrialization Plan for Early Stage Start Ups
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Patrick Gailliot, Sr. Director, Patient Operations, Abeona Therapeutics
Nov 514:05
Conference pass
Novel approach for manufacturing of large scale high titer gamma retroviral vectors in small academic GMP facility
Viral Vector Manufacturing (Track 3)
Bipasha Barua, Process Development Lead, Immune, Cell and Gene Therapy GMP/PD Facility, Rutgers Cancer Institute, Rutgers University
Nov 514:05
Conference pass
Opus Genetics clinical update on 6 ophthalmic trials
Gene Therapy (Track 4)
Sally Tucker, Chief Medical Officer, Opus Genetics
Nov 514:05
Conference pass
Panel Discussion: Considerations for Successful Clinical Trial Design
Pre-Clinical & Clinical (Track 6, Room 207)
Prasad Adusumilli, Deputy Chief, Thoracic Surgery, Vice Chair, Department Of Surgery, Memorial Sloan-Kettering Cancer Center
Manoj Kandpal, Director of Research Bioinformatics at the Center for Clinical and Translational Science, Rockefeller University
Moderator: Prachi Narayan, End-to-End Clinical & Development Lead and Strategic Advisor– ATMPs, Independent Expert
Nov 514:05
Conference pass
Panel Discussion: Manufacturing Strategies: Decentralised Vs. Centralised Approaches for Cell Therapies
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Moderator: Mark Dudley, Consultant, Independent Advisors
Therese Choquette, Chief Technical Officer, Tigen Pharma
Steven Feldman, Site Head and Scientific Director, Stanford GMP Facility, Stanford School of Medicine/Stanford HealthCare
Nov 514:05
Conference pass
Panel Discussion: Navigating the Global Regulatory Landscape for Commercial Approval
Regulatory Affairs & Policy (Track 8, Room 209)
Moderator: Lara Silverman, Principal Consultant, L.I.S. BioConsulting
Jim Wang, VP, Global Regulatory Strategy, Genetic Medicines, Regeneron
Hugh Gannon, Associate Director, KSQ Therapeutics, Inc.
Nidhi Kotecha, Program Director, Regulatory Affairs, Gates Institute
Nov 514:05
Conference pass
Panel Discussion: Top Tips for Attracting Investment
Innovation Showcase (Track 5, Seminar Theatre)
Fiona Miller, Managing Partner, quadraScope Ventures
Mary Schaheen, President, Prevail Partners LLC
Minghong Zhong, CEO, GeneLancet Biosciences, Inc.
Nov 514:25
Conference pass
Developing an efficient strategy for on-boarding emerging therapies
Gene Therapy (Track 4)
Colleen Dansereau, Vice President, Emerging Discoveries, Gene Therapy Operations, Boston Children's Hospital
Nov 514:25
Conference pass
Engineering regulatory T cells (Tregs) for immune tolerance and transplantation
Gene Modified Cell Therapy (Track 7, Room 208)
Subhash Tripathi, Assistant Professor of Immunology, Appalachian State University
Nov 514:25
Conference pass
Lineage-selective in vivo CAR NK from self-renewing hematopoietic stem cells
Gene Modified Cell Therapy (Track 7, Room 208)
Nov 514:25
Conference pass
Phase 1 experience with CD19/CD20 dual targeting GF-CART01 for B cell lymphomas
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Sareina Wu, Founder & CSO, Genomefrontier Therapeutics Inc
Nov 514:25
Conference pass
PRINT transgene insertion for the treatment of Fabry disease and hypothalamic obesity
Gene Therapy (Track 4)
Suvi Jain, Executive Director, Preclinical Translation, Addition Therapeutics
Nov 514:25
Conference pass
Process Characterization Strategy to Support an Accelerated BLA-Enabling Pathway for AAV Gene Therapy
Viral Vector Manufacturing (Track 3)
Jack Ren, Director, Global CMC Development, Ultragenyx Pharmaceutical Inc
Nov 515:15
Conference pass
Chair's Remarks: Angela Justice, Founder, Justice Group Advisors
Innovation Showcase (Track 5, Seminar Theatre)
Nov 515:15
Conference pass
Chair's Remarks: David Peritt, Chief Scientific Officer, Lupagen
Gene Modified Cell Therapy (Track 7, Room 208)
David Peritt, Chief Scientific Officer, Lupagen
Nov 515:15
Conference pass
Chair's Remarks: Deb Bhattacharya, Vice President, CMC Technical Development, MyrtelleGTX
Viral Vector Manufacturing (Track 3)
Debaditya Bhattacharya, Vice President, CMC Technical Development, MyrtelleGTX
Nov 515:15
Conference pass
Chair's Remarks: Kunjan Kamdar, Director Quality Assurance & Regulatory Affairs at Laboratory for Cell & Gene Medicine, Stanford GMP Facility: Laboratory for Cell and Gene Medicine
Regulatory Affairs & Policy (Track 8, Room 209)
Kunjan Kamdar, Director Quality Assurance & Regulatory Affairs at Laboratory for Cell & Gene Medicine, Stanford GMP Facility: Laboratory for Cell and Gene Medicine
Nov 515:15
Conference pass
Chair's Remarks: Manoj Kandpal, Director of Research Bioinformatics at the Center for Clinical and Translational Science, Rockefeller University
Pre-Clinical & Clinical (Track 6, Room 207)
Manoj Kandpal, Director of Research Bioinformatics at the Center for Clinical and Translational Science, Rockefeller University
Nov 515:15
Conference pass
Chair's Remarks: Michael McMahon, Professor, Johns Hopkins School of Medicine and Kennedy Krieger Institute
Gene Therapy (Track 4)
Michael McMahon, Professor, Johns Hopkins School of Medicine and Kennedy Krieger Institute, John Hopkins School Of Medicine
Nov 515:15
Conference pass
Chair's Remarks: Niraj Ramachandran, Senior Regulatory Program Director - Cellular Therapies Pharma Technical Cell and Gene Therapy (PTC), Genentech
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Nov 515:15
Conference pass
Chair's Remarks:Baochun Zhang, Assistant Professor of Medicine, Harvard Medical School
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Nov 515:20
Conference pass
Advancements in Cell Therapy: Development of a Non-Viral Gene Delivery Platform for CAR-T Manufacturing
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Steven Feldman, Site Head and Scientific Director, Stanford GMP Facility, Stanford School of Medicine/Stanford HealthCare
Nov 515:20
Conference pass
Analytical strategy for early gene therapy development
Gene Therapy (Track 4)
Rajeev Boregowda, Associate Director, Sanofi
Nov 515:20
Conference pass
BTX-001 - an intravitreal gene therapy for geographical atrophy
Pre-Clinical & Clinical (Track 6, Room 207)
Nov 515:20
Conference pass
CMC regulatory strategy for potency assays for cell and gene therapies
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Nov 515:20
Conference pass
Driving Manufacturing Consistency and Quality through International Standards and Interlaboratory Study Reference Material Characterization
Viral Vector Manufacturing (Track 3)
Nov 515:20
Conference pass
From Innovation to patient access: EATRIS solutions
Innovation Showcase (Track 5, Seminar Theatre)
David Morrow, Scientific Lead for Advanced Therapies, EATRIS
Nov 515:20
Conference pass
Regulatory playbook for CNS gene therapy – TfR1 CapX from bench to clinic
Regulatory Affairs & Policy (Track 8, Room 209)
Jorge Santiago Ortiz, VP, CMC and Regulatory, Apertura Gene Therapy
Nov 515:20
Conference pass
Transposon-Based CAR-T cells
Gene Modified Cell Therapy (Track 7, Room 208)
Luiza Abdo, PhD, Brazilian National Cancer Institute
Nov 515:40
Conference pass
AI for clinical trials: Driving efficiency and representation in clinical research
Pre-Clinical & Clinical (Track 6, Room 207)
Alexander Blood, Director, Accelerator for Clinical Transformation, Mass General Brigham
Nov 515:40
Conference pass
IND preparedness for cell & gene therapies
Regulatory Affairs & Policy (Track 8, Room 209)
Nidhi Kotecha, Program Director, Regulatory Affairs, Gates Institute
Nov 515:40
Conference pass
International standards for characterising and testing cell therapy products
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Sumona (Fed) Sarkar, Biomedical Engineer, NIST USA
Nov 515:40
Conference pass
Next-generation precise CRISPR gene editing with chemically ligated guide RNAs
Gene Modified Cell Therapy (Track 7, Room 208)
Minghong Zhong, CEO, GeneLancet Biosciences, Inc.
Nov 515:40
Conference pass
Optimization and application of HSV vectors
Viral Vector Manufacturing (Track 3)
Selene Ingusci, Research Instructor, University of Pittsburgh
Nov 515:40
Conference pass
Tech transfer and scaling-up for the success of cell therapy programs
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Nov 515:40
Conference pass
Unlocking Precision Gene Editing with AI
Gene Therapy (Track 4)
Chelsea Trengrove, CEO and Cofounder, Neoclease
Nov 515:40
Conference pass
Use of novel bio-materials to create and enhance therapeutics
Innovation Showcase (Track 5, Seminar Theatre)
Pierre Dromel, CTO & Founder, InGel Therapeutics
Nov 516:00
Conference pass
Clinical scale cell therapy manufacturing on a chip
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Avanish Mishra, Assistant Professor of Bioengineering, Harvard Medical School and Mass General Hospital, Harvard Medical School
Nov 516:00
Conference pass
Ensuring safety in regulatory submissions through off-targets and genotoxicity
Regulatory Affairs & Policy (Track 8, Room 209)
Hugh Gannon, Associate Director, KSQ Therapeutics, Inc.
Nov 516:00
Conference pass
From Genes to Clinic: Advancing Gene Therapies for Hereditary Hearing Loss
Gene Therapy (Track 4)
Els Henckaerts, Professor, KU Leuven
Nov 516:00
Conference pass
In vivo generation of therapeutic immune cells: CAR-T and Beyond
Gene Modified Cell Therapy (Track 7, Room 208)
David Peritt, Chief Scientific Officer, Lupagen
Nov 516:00
Conference pass
LVV economics: It’s not what you think
Viral Vector Manufacturing (Track 3)
Mark Davis, Principal, NegotiumBio, LLC
Nov 516:00
Conference pass
Multiantigen-targeted Cytotoxic CD4+ T Cells for Cancer Therapy
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Nov 516:00
Conference pass
Rewards and challenges of being a one-stop shop for cell therapy manufacturing in an academic medical center
Pre-Clinical & Clinical (Track 6, Room 207)
Lynn O'Donnell, Director, Cell Therapy Manufacturing & Engineering, The Ohio State University
Nov 516:00
Conference pass
Using venture philanthropy to drive innovative therapies
Innovation Showcase (Track 5, Seminar Theatre)
Nov 516:20
Conference pass
CXR101 pre-clinical development for head & neck cancer
Pre-Clinical & Clinical (Track 6, Room 207)
Nov 516:20
Conference pass
Developing a HIV cure with cell therapies
Gene Modified Cell Therapy (Track 7, Room 208)
Yuntao Wu, Professor, George Mason University
Nov 516:20
Conference pass
Developing Point-of-Care Manufacturing of Cell Therapy Products in an Academic Institution Laboratory
Cell Therapy Sponsored by Cellares Corporation (Track 1, Keynote Theatre)
Nov 516:20
Conference pass
From Protocol to Patient: Strategies for Successful Cell and Gene Therapy Clinical Trial Delivery
Innovation Showcase (Track 5, Seminar Theatre)
Nov 516:20
Conference pass
Nov 516:20
Conference pass
Scaling up production of hiPSC-derived HSCs and CAR-T cells
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 2)
Thorsten Schlaeger, Principal Investigator and Director of the Stem Cell Core Lab, Boston Children's Hospital
last published: 21/Sep/26 12:56 GMT
Get Involved with the Advanced Therapies Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events